Immediate and Delayed Hypersensitivity Reactions to a Single Dose of Oxaliplatin

Grewal, Guranjan D; Badrick, Timothy C.; Gilbar, Peter J

doi:10.1016/j.clcc.2014.12.010

Cited by 7 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The usually encountered adverse reaction is peripheral neuropathy which can be acute or chronic. 7 Hypersensitivity reactions to oxaliplatin, which are type I in nature, have been reported in about 10-25% of cases, whereas cases of severe hypersensitivity reported is only 0.5%. 1,7,8 Features of hypersensitivity reactions include minor reactions like rash, urticaria, flushing, itching, abdominal cramps, diarrhoea, and back pain and severe symptoms can manifest as tachycardia, bronchospasm, stridor, dysphonia, hypotension or hypertension and seizures.…”

Section: Discussionmentioning

confidence: 99%

“…7 Hypersensitivity reactions to oxaliplatin, which are type I in nature, have been reported in about 10-25% of cases, whereas cases of severe hypersensitivity reported is only 0.5%. 1,7,8 Features of hypersensitivity reactions include minor reactions like rash, urticaria, flushing, itching, abdominal cramps, diarrhoea, and back pain and severe symptoms can manifest as tachycardia, bronchospasm, stridor, dysphonia, hypotension or hypertension and seizures. 9 The incidence of laryngospasm due to oxaliplatin, is less when compared to other adverse effects but can be fatal if not diagnosed and managed early.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Oxaliplatin induced laryngospasm: a case series

George¹,

Anuradha²

2019

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Oxaliplatin is a third-generation platinum derivative used as a first-line agent in the treatment of colorectal carcinoma, biliary tract cancer and gastric cancers and can be used as a neoadjuvant/adjuvant in these cancers. The dose limiting toxicity is peripheral neuropathy, others include hypersensitivity reactions, haematological toxicity and pulmonary fibrosis. Hypersensitivity reactions can extend from milder reactions like urticaria, rash to severe symptoms like hypotension and laryngospasm. The laryngospasm due to oxaliplatin is reported to be reversible with corticosteroids, antihistamines and oxygen. This case series suggest that oxaliplatin has a propensity to cause severe hypersensitivity reaction presenting as laryngospasm not with a single dose but with subsequent doses of oxaliplatin. Prompt symptomatic treatment with corticosteroids leads to reversal of symptoms and improvement in the condition of the patient.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Oxaliplatin induced laryngospasm: a case series

George¹,

Anuradha²

2019

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Moreover, there were no allergic reactions or cardiotoxicity during transarterial infusion with raltitrexed, and no studies to date have reported any adverse events in this context. In contrast, allergic reactions and cardiotoxicity frequently occur when antitumor drugs such as oxaliplatin and epirubicin are used [ 10 , 21 - 23 ]. These results indicate that the combination of raltitrexed and oxaliplatin in TACE in patients with unresectable HCC is safe and tolerable.…”

Section: Discussionmentioning

confidence: 99%

Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin

et al. 2017

View full text Add to dashboard Cite

AimsTo compare the safety and efficacy of TACE using raltitrexed, oxaliplatin and epirubicin with 5-fluorouracil, oxaliplatin and epirubicin for patients with unresectable hepatocelluar carcinoma.ResultsMedian overall survival (OS) was 7.4 months in the raltitrexed group [95% confidence interval (CI): 5.4, 9.4) and 5.8 months in the control group (95% CI: 5.2, 6.4; P = 0.177). The median progression-free survival (PFS) time was significantly higher in the raltitrexed group (3.6 months, 95% CI: 2.8, 4.4) than in the control group (2.6 months, 95% CI: 2.2, 3.0; P = 0.038). The disease control rate (DCR) was higher in the raltitrexed group than in the control group (40% versus 30.4%; P = 0.353). The incidence of adverse events was similar between the two groups.Materials and MethodsFrom January 2012 to December 2014, 86 patients with unresectable HCC were treated with TACE using the combination of raltitrexed, oxaliplatin and epirubicin (raltitrexed group), and the combination of 5-fluorouracil, oxaliplatin and epirubicin (control group). The primary endpoint was OS, and the secondary endpoints were PFS, DCR and adverse events.ConclusionsAlthough the study did not meet its primary endpoint, raltitrexed group reach a higher PFS, which suggests that this combination regimen of TACE as alternative may confer some benefits to selected patients.

show abstract

“…Moreover, our figures showed that no patients experienced allergic reactions while HAI with raltitrexed, and no studies have reported allergic reactions to raltitrexed. However, allergic reactions related to oxaliplatin, epirubicin, and other anti-cancer drugs are frequently reported in the literature [17,21,22].…”

Section: Discussionmentioning

confidence: 99%